Cytosorbents (NASDAQ:CTSO) was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued on Tuesday.

Several other equities analysts also recently weighed in on CTSO. Cowen reiterated a “buy” rating and set a $15.00 target price on shares of Cytosorbents in a research report on Friday, August 3rd. Maxim Group reiterated a “buy” rating and set a $18.00 target price on shares of Cytosorbents in a research report on Tuesday, September 4th. Finally, HC Wainwright set a $15.00 price target on Cytosorbents and gave the stock a “buy” rating in a research note on Wednesday, November 7th. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $14.81.

NASDAQ CTSO traded down $0.14 during trading hours on Tuesday, hitting $9.54. 123,000 shares of the company’s stock were exchanged, compared to its average volume of 244,571. Cytosorbents has a 12-month low of $5.80 and a 12-month high of $14.95. The company has a market capitalization of $311.77 million, a PE ratio of -29.81 and a beta of 0.62. The company has a current ratio of 7.03, a quick ratio of 6.85 and a debt-to-equity ratio of 0.49.

Cytosorbents (NASDAQ:CTSO) last released its earnings results on Wednesday, November 7th. The medical research company reported ($0.10) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.04. Cytosorbents had a negative return on equity of 90.18% and a negative net margin of 70.97%. The firm had revenue of $5.74 million for the quarter, compared to the consensus estimate of $5.79 million. Equities analysts predict that Cytosorbents will post -0.51 EPS for the current year.

In other Cytosorbents news, COO Vincent Capponi sold 9,565 shares of the company’s stock in a transaction dated Tuesday, August 28th. The stock was sold at an average price of $13.00, for a total transaction of $124,345.00. Following the completion of the sale, the chief operating officer now directly owns 342,333 shares in the company, valued at $4,450,329. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Al Kraus sold 26,000 shares of the company’s stock in a transaction dated Thursday, August 30th. The stock was sold at an average price of $14.47, for a total value of $376,220.00. Following the sale, the director now owns 133,046 shares of the company’s stock, valued at $1,925,175.62. The disclosure for this sale can be found here. Insiders have sold 65,501 shares of company stock valued at $927,310 over the last 90 days. 6.90% of the stock is currently owned by insiders.

Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. grew its stake in shares of Cytosorbents by 14.9% in the third quarter. BlackRock Inc. now owns 1,961,749 shares of the medical research company’s stock valued at $25,308,000 after buying an additional 254,902 shares in the last quarter. Millennium Management LLC grew its stake in shares of Cytosorbents by 134.4% in the first quarter. Millennium Management LLC now owns 384,330 shares of the medical research company’s stock valued at $2,710,000 after buying an additional 220,353 shares in the last quarter. Allianz Asset Management GmbH grew its stake in shares of Cytosorbents by 35.9% in the third quarter. Allianz Asset Management GmbH now owns 350,178 shares of the medical research company’s stock valued at $4,517,000 after buying an additional 92,508 shares in the last quarter. Northern Trust Corp grew its stake in shares of Cytosorbents by 542.8% in the second quarter. Northern Trust Corp now owns 309,268 shares of the medical research company’s stock valued at $3,526,000 after buying an additional 261,154 shares in the last quarter. Finally, Manatuck Hill Partners LLC grew its stake in shares of Cytosorbents by 4.9% in the second quarter. Manatuck Hill Partners LLC now owns 258,200 shares of the medical research company’s stock valued at $2,943,000 after buying an additional 12,000 shares in the last quarter. Institutional investors and hedge funds own 24.79% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.

Further Reading: Growth Stocks

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.